Platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on T cell receptor (TCR) targeting solid tumours
Engimmune Therapeutics has raised €16M across 2 funding rounds from 3 investors, most recently a Seed round in May 2022. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-05-03 | Seed | €15M | Novo Holdings,Pureos Bioventures | View deal → |
| 2022-02-21 | Other | €481k | BaseLaunch | View deal → |
